Cargando…

Rapamycin improves Graves’ orbitopathy by suppressing CD4(+) cytotoxic T lymphocytes

CD4(+) cytotoxic T lymphocytes (CTLs) were recently implicated in immune-mediated inflammation and fibrosis progression of Graves’ orbitopathy (GO). However, little is known about therapeutic targeting of CD4(+) CTLs. Herein, we studied the effect of rapamycin, an approved mTOR complex 1 (mTORC1) in...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Meng, Chong, Kelvin K.L., Chen, Zi-yi, Guo, Hui, Liu, Yu-feng, Kang, Yong-yong, Li, Yang-jun, Shi, Ting-ting, Lai, Kenneth K.H., He, Ming-qian, Ye, Kai, Kahaly, George J., Shi, Bing-yin, Wang, Yue
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society for Clinical Investigation 2023
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9977423/ https://www.ncbi.nlm.nih.gov/pubmed/36580373 http://dx.doi.org/10.1172/jci.insight.160377

Ejemplares similares

Graves' Orbitopathy
por: Hiromatsu, Yuji, et al.
Publicado: (2015)

Thyrotropin receptor antibodies and Graves’ orbitopathy
por: Diana, T., et al.
Publicado: (2020)

Correction to: Thyrotropin receptor antibodies and Graves’ orbitopathy
por: Diana, T., et al.
Publicado: (2021)

Glucocorticoids in Graves’ orbitopathy: mechanisms of action and clinical application
por: Längericht, Jan, et al.
Publicado: (2020)

Stimulatory Thyrotropin Receptor Antibodies Are a Biomarker for Graves’ Orbitopathy
por: George, Augustine, et al.
Publicado: (2021)

SAT-429 Systemic Safety Analysis of Mycophenolate in Graves’ Orbitopathy
por: Lee, Alan C H, et al.
Publicado: (2020)

Graves’ orbitopathy as a rare disease in Europe: a European Group on Graves’ Orbitopathy (EUGOGO) position statement
por: Perros, P., et al.
Publicado: (2017)

SAT-554 Teprotumumab in Graves' Orbitopathy: Extended Outcome Analyses
por: Kahaly, George, et al.
Publicado: (2019)

Asymmetric Graves’ Orbitopathy
por: Panagiotou, Grigorios, et al.
Publicado: (2020)

Editorial: Mechanisms and Novel Therapies in Graves’ Orbitopathy: Current Update
por: Zhou, Huifang, et al.
Publicado: (2022)

Teprotumumab: a disease modifying treatment for graves’ orbitopathy
por: Ting, Michelle, et al.
Publicado: (2020)

The Role of the Microbiota in Graves’ Disease and Graves’ Orbitopathy
por: Hou, Jueyu, et al.
Publicado: (2021)

Antioxidant Therapy in Graves’ Orbitopathy
por: Lanzolla, Giulia, et al.
Publicado: (2020)

Current Knowledge on Graves’ Orbitopathy
por: Gontarz-Nowak, Katarzyna, et al.
Publicado: (2020)

Orbital Signaling in Graves’ Orbitopathy
por: Draman, Mohd Shazli, et al.
Publicado: (2021)

Graves’ disease and Graves’ orbitopathy following COVID-19
por: Lanzolla, G., et al.
Publicado: (2021)

Anti-nuclear autoantibodies in Graves’ disease and Graves’ orbitopathy
por: Lanzolla, G., et al.
Publicado: (2022)

The Potential Link between Gut Microbiota and Serum TRAb in Chinese Patients with Severe and Active Graves' Orbitopathy
por: Shi, Ting-Ting, et al.
Publicado: (2019)

Serum thyroglobulin is associated with orbitopathy in Graves’ disease
por: Khamisi, S., et al.
Publicado: (2021)

Graves′ orbitopathy: Management of difficult cases
por: Wiersinga, Wilmar M.
Publicado: (2012)

Endoscopic orbital decompression for Graves’ orbitopathy
por: Lal, Priti, et al.
Publicado: (2013)

Current concepts regarding Graves’ orbitopathy
por: Bartalena, Luigi, et al.
Publicado: (2022)

Update on the surgical management of Graves’ orbitopathy
por: Baeg, Joonyoung, et al.
Publicado: (2023)

Significance of HLA in the development of Graves’ orbitopathy
por: Stasiak, Magdalena, et al.
Publicado: (2023)

The value of SPECT/CT imaging of lacrimal glands as a means of assessing the activity of Graves’ orbitopathy
por: Zhao, Ru-Xuan, et al.
Publicado: (2022)

The Clinical Features of Graves' Orbitopathy with Elevated Intraocular Pressure
por: Fan, Shu-Xian, et al.
Publicado: (2021)

Identifying and Validating Genes with DNA Methylation Data in the Context of Biological Network for Chinese Patients with Graves' Orbitopathy
por: Shi, Ting-Ting, et al.
Publicado: (2019)

A Pathway Analysis Based on Genome-Wide DNA Methylation of Chinese Patients with Graves' Orbitopathy
por: Xin, Zhong, et al.
Publicado: (2019)

Planning health care for patients with Graves’ orbitopathy
por: Sasim, Inna V., et al.
Publicado: (2008)

Surgical complications in orbital decompression for Graves' orbitopathy
por: Sellari-Franceschini, S., et al.
Publicado: (2016)

Mechanisms That Underly T Cell Immunity in Graves’ Orbitopathy
por: Fang, Sijie, et al.
Publicado: (2021)

Roles of four targets in the pathogenesis of graves' orbitopathy
por: Ren, Ziqiang, et al.
Publicado: (2023)

Atypical Asymmetric Presentation of Severe Graves’ Orbitopathy
por: Gupta, Priyanka, et al.
Publicado: (2023)

Epidemiology, Natural History, Risk Factors, and Prevention of Graves’ Orbitopathy
por: Bartalena, Luigi, et al.
Publicado: (2020)

Neferine suppresses autophagy‐induced inflammation, oxidative stress and adipocyte differentiation in Graves' orbitopathy
por: Li, Hong, et al.
Publicado: (2021)

Traditional Chinese medicine in thyroid-associated orbitopathy
por: Hai, Y. P., et al.
Publicado: (2023)

Endoscopic intranasal orbital decompression in the course of Graves’ orbitopathy
por: Krzeski, Antoni, et al.
Publicado: (2013)

Association between Polymorphisms in the TSHR Gene and Graves' Orbitopathy
por: Jurecka-Lubieniecka, Beata, et al.
Publicado: (2014)

Not All Orbitopathy Is Graves’: Discussion of Cases and Review of Literature
por: Boddu, Neeraja, et al.
Publicado: (2017)

Factors associated with severity of orbitopathy in patients with Graves' disease
por: Nabi, Tauseef, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_9ps21gaj8o27jt14nrchde04q3